Wird geladen...
Pasireotide and Octreotide Stimulate Distinct Patterns of sst(2A) Somatostatin Receptor Phosphorylation
Pasireotide (SOM230) is currently under clinical evaluation as a successor compound to octreotide for the treatment of acromegaly, Cushing’s disease, and carcinoid tumors. Whereas octreotide acts primarily via the sst(2A) somatostatin receptor, pasireotide was designed to exhibit octreotide-like sst...
Gespeichert in:
| Veröffentlicht in: | Mol Endocrinol |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Endocrine Society
2010
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5428126/ https://ncbi.nlm.nih.gov/pubmed/20051480 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/me.2009-0315 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|